Biogen, Eisai's BAN2401 slows AD progression at 18 months

Biogen Inc. (NASDAQ:BIIB) and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary endpoint data on July 5 showing that the highest dose of BAN2401 significantly slowed disease progression and reduced beta amyloid at 18 months in the double-blind Phase II Study 201 to treat Alzheimer's disease.

The trial missed its primary endpoint late last year; however,

Read the full 545 word article

User Sign In